CG Oncology executives to present at investor conferences on bladder cancer therapeutic developments in September 2025.
Quiver AI Summary
CG Oncology, Inc., a biopharmaceutical company focused on developing a bladder-sparing therapy for bladder cancer patients, announced that its Chairman and CEO, Arthur Kuan, and President and COO, Ambaw Bellete, will speak at two upcoming investor conferences: the Cantor Global Healthcare Conference on September 5, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. Both presentations will be available via live audio webcast on the company's website, with replays accessible for approximately 90 days afterward. CG Oncology aims to enhance the quality of life for urologic cancer patients through innovative immunotherapies.
Potential Positives
- Participation in two significant investor conferences highlights CG Oncology's commitment to engaging with the investor community and promoting its therapeutic developments.
- The scheduled appearances by high-level executives, including the CEO and COO, indicate strong leadership presence and confidence in the company's future.
- Access to live audio webcasts allows broader audience engagement, increasing visibility and potential interest from investors.
Potential Negatives
- Limited information on the company's current financial status or funding could raise concerns among investors about the viability and potential commercialization of their therapeutic products.
- The focus on upcoming presentations may indicate a lack of recent significant developments or breakthroughs in clinical trials, which could affect investor confidence.
- No substantive data or results from ongoing clinical trials were provided, which may lead to skepticism regarding the effectiveness and safety of their therapies.
FAQ
What is CG Oncology focused on?
CG Oncology is focused on developing and commercializing bladder-sparing therapeutics for bladder cancer patients.
When are the upcoming investor conferences where CG Oncology will present?
CG Oncology will participate in the Cantor Global Healthcare Conference on September 5, 2025, and the Morgan Stanley Global Healthcare Conference on September 9, 2025.
How can I access the live audio webcast of the CG Oncology presentations?
The live audio webcast can be accessed from the Investor Relations section of CG Oncology's website at www.cgoncology.com.
How long will the webcast replay be available after the live presentations?
The webcast replay will be available shortly after the conclusion of the live presentation and archived for approximately 90 days.
Who are the key executives presenting at the investor conferences?
Arthur Kuan, Chairman & CEO, and Ambaw Bellete, President & COO, will present at the conferences.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CGON Insider Trading Activity
$CGON insiders have traded $CGON stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $CGON stock by insiders over the last 6 months:
- LEONARD E POST has made 0 purchases and 4 sales selling 5,000 shares for an estimated $142,760.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CGON Hedge Fund Activity
We have seen 115 institutional investors add shares of $CGON stock to their portfolio, and 67 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARSHALL WACE, LLP removed 2,418,456 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $62,879,856
- BANK OF AMERICA CORP /DE/ added 1,396,170 shares (+409.9%) to their portfolio in Q2 2025, for an estimated $36,300,420
- FMR LLC added 1,311,163 shares (+51.5%) to their portfolio in Q2 2025, for an estimated $34,090,238
- JANUS HENDERSON GROUP PLC removed 1,259,241 shares (-98.6%) from their portfolio in Q2 2025, for an estimated $32,740,266
- PRICE T ROWE ASSOCIATES INC /MD/ added 999,094 shares (+98.5%) to their portfolio in Q2 2025, for an estimated $25,976,444
- CITADEL ADVISORS LLC removed 963,665 shares (-84.6%) from their portfolio in Q2 2025, for an estimated $25,055,290
- MORGAN STANLEY added 923,067 shares (+97.7%) to their portfolio in Q2 2025, for an estimated $23,999,742
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CGON Analyst Ratings
Wall Street analysts have issued reports on $CGON in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 08/19/2025
- RBC Capital issued a "Outperform" rating on 07/16/2025
- Morgan Stanley issued a "Overweight" rating on 06/17/2025
- JP Morgan issued a "Overweight" rating on 05/02/2025
- Cantor Fitzgerald issued a "Overweight" rating on 04/28/2025
- HC Wainwright & Co. issued a "Buy" rating on 04/28/2025
To track analyst ratings and price targets for $CGON, check out Quiver Quantitative's $CGON forecast page.
$CGON Price Targets
Multiple analysts have issued price targets for $CGON recently. We have seen 8 analysts offer price targets for $CGON in the last 6 months, with a median target of $55.5.
Here are some recent targets:
- Kelsey Goodwin from Piper Sandler set a target price of $55.0 on 08/19/2025
- Leonid Timashev from RBC Capital set a target price of $53.0 on 07/16/2025
- Jeffrey Hung from Morgan Stanley set a target price of $56.0 on 06/17/2025
- Brian Cheng from JP Morgan set a target price of $41.0 on 05/02/2025
- Josh Schimmer from Cantor Fitzgerald set a target price of $75.0 on 04/28/2025
- Andres Maldonado from HC Wainwright & Co. set a target price of $75.0 on 04/28/2025
- An analyst from Scotiabank set a target price of $23.0 on 04/16/2025
Full Release
IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, are scheduled to participate in fireside chat presentations at the following investor conferences:
- Cantor Global Healthcare Conference – presenting Friday, September 5, 2025, at 10:20am ET in New York, NY
-
Morgan Stanley 23rd Annual Global Healthcare Conference – presenting Tuesday, September 9, 2025, at 7:45am ET in New York, NY
Interested parties may access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com . The webcast replay will be available shortly after the conclusion of the live presentation and archived for approximately 90 days.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts:
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
[email protected]
Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
[email protected]
